Meet Edsel Bester, the newest bird in our bPACE flock! Learn more about his experience working with the communities that bluebird bio serves and how he defines a perfect bluebird day. If you see Edsel at an upcoming community event, make sure you say hi!
bluebird bio
Biotechnology Research
Somerville, Massachusetts 136,516 followers
Pursuing curative gene therapies to give patients and their families more bluebird days.
Über uns
bluebird bio is pursuing curative gene therapies to give patients and their families more bluebird days. With a dedicated focus on severe genetic diseases, bluebird has industry-leading programs for sickle cell disease, β-thalassemia and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. We custom design each of our therapies to address the underlying cause of disease and have developed in-depth and effective analytical methods to understand the safety of our lentiviral vector technologies and drive the field of gene therapy forward. Founded in 2010, bluebird has the largest and deepest ex-vivo gene therapy data set in the world—setting the standard for the industry. Today, bluebird continues to forge new paths, combining our real-world experience with a deep commitment to patient communities and a people-centric culture that attracts and grows a diverse flock of dedicated birds. Community guidelines: http://bit.ly/bbbGuidelines
- Website
-
http://www.bluebirdbio.com
External link for bluebird bio
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 201-500 Mitarbeiter
- Hauptsitz
- Somerville, Massachusetts
- Typ
- Öffentliches Unternehmen
- Gegründet
- 1993
- Spezialitäten
- gene therapy, gene addition, sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy
Standorte
-
Primäre
Wegbeschreibung erhalten
455 Grand Union Blvd
Somerville, Massachusetts 02145, US
Employees at bluebird bio
Aktualisierungen
-
Today, bluebird bio reported second quarter 2024 results and business highlights. Swipe through for updates related to our commercial progress and learn more here: https://lnkd.in/eiwwVPjZ
-
Holy COW, the flock had a great time at the Cooley's Anemia Foundation Patient-Family Conference! It's always an honor connecting with the #betathalassemia community and learning more about how we can better serve people living with beta-thalassemia. And it’s especially fun when our Director of Patient Advocacy, Susan Brisendine, gets the chance to rock her inflatable cow costume at the conference’s costume party! 🐮
-
Welcome to our bPACE birds’ series! Did you know we have a specific flock of birds, bPACE, who work to educate the communities we serve about gene therapy? Meet Phill Okwo, Director of Patient and Community Education, one of our birds who soars to great heights. Learn more about Phill and what inspires him.
-
The SICKLE CELL CONSORTIUM's Annual Warriors Conference is back! Our flock is flying down to Atlanta to connect with others in the sickle cell community and share more about our approach to gene therapy treatment. Opportunities like these remind us of how far we've come and all the great work that's yet to be done!
-
-
The flock and bWILD, bluebird’s Women Influencing Leadership Development ERG, are so grateful to Kendalle Burlin O'Connell, Esq. for sharing her powerful story and her insights on the future of biotech at a fireside chat at the nest. Thank you for joining us!
CEO & President, MassBio | Chair, Bioversity | Board, The Boston Foundation | Vice Chair, American Cancer Society (ACS) Eastern New England | Board, MassBioEd Foundation
So much fun spending time at bluebird bio’s nest in Somerville, meeting with leadership and engaging with the flock responsible for delivering for patients. bluebird has such an incredible company culture that shines through the passion of everyone who works there. Love that the fireside chat was organized by your bWild ERG, which embodies your commitment to women and leadership development. Your gene therapies are changing the lives of people with #rarediseases, including most recently those with sickle cell disease and β-thalassemia. Thank you to CEO Andrew Obenshain and SVP Sarah Alspach for hosting our team. Your #patientdriven efforts are recognized and celebrated!
-
Ähnliche Seiten
Jobs durchsuchen
Aktie
BLUE
NASDAQ
20 Minuten Verzögerung
$0.62
-0.007 (-1.095%)
- Öffnen Sie
- 0.637
- Niedrig
- 0.603
- Hoch
- 0.656
Daten von Refinitiv
Siehe mehr Informationen auf